Minerva Neurosciences, Inc. (NERV) has a negative trailing P/E of -0.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 65.1 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -508.02%, forward earnings yield 1.54%. PEG 0.08 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -11.9 | 0.81 | 3.49 | 0.00 | - |
| 2017 | -7.3 | 0.47 | 1.74 | 0.00 | - |
| 2018 | -5.2 | -0.09 | 2.90 | 0.00 | - |
| 2019 | -3.8 | -0.09 | 9.99 | 0.00 | - |
| 2020 | 49.2 | -0.48 | 1.81 | 2.32 | - |
| 2021 | -0.7 | 0.00 | 4.29 | 0.00 | - |
| 2022 | -0.3 | 0.01 | -0.42 | 0.00 | - |
| 2023 | -1.3 | 0.06 | -1.41 | 0.00 | - |
| 2024 | 11.7 | -0.11 | -0.65 | 0.00 | - |
| 2025 | -0.1 | 0.00 | -0.24 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-7.88 | $0.00 | $-31.05M | - |
| 2017 | $-6.65 | $0.00 | $-31.52M | - |
| 2018 | $-10.35 | $0.00 | $-50.17M | - |
| 2019 | $-14.80 | $0.00 | $-72.18M | - |
| 2020 | $0.38 | $41.18M | $1.94M | 4.7% |
| 2021 | $-9.35 | $0.00 | $-49.91M | - |
| 2022 | $-6.01 | $0.00 | $-32.11M | - |
| 2023 | $-4.61 | $0.00 | $-30.01M | - |
| 2024 | $0.19 | $0.00 | $1.44M | - |
| 2025 | $-34.67 | $0.00 | $-293.42M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.74 | $-0.74 – $-0.74 | $19.76M | $19.76M – $19.76M | 1 |
| 2027 | $-0.63 | $-0.63 – $-0.63 | $56.49M | $56.49M – $56.49M | 1 |
| 2028 | $-0.37 | $-0.44 – $-0.29 | $19.12M | $19.12M – $19.12M | 2 |
| 2029 | $0.10 | $0.10 – $0.10 | $80.86M | $80.86M – $80.86M | 1 |
| 2030 | $0.88 | $0.88 – $0.88 | $221.38M | $221.38M – $221.38M | 1 |
